BeyondSpring Inc (BYSI)
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company’s programs are organized around its Plinabulin pipeline and TPD platform. Its lead candidate, Plinabulin, is a selective immunomodulating microtubule-binding agent that has completed Phase III trials in non-small cell lung cancer and for the prevention of chemotherapy-induced neutropenia. BeyondSpring is also evaluating Plinabulin in combination with docetaxel for NSCLC, as well as with several immuno-oncology agents, chemotherapy, and radiation in additional cancer settings. The company is further developing several small-molecule immune agents in preclinical stages and maintains a drug discovery platform supported by internal research and collaboration. Founded in 2010, BeyondSpring is headquartered in Florham Park, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BYSI
|
$0.75
|
1.7% Upside
|
Fair
|
Not available
|
Not available
|
Fair
|
0.0%
|
December 17, 2026
|
30.441 M
|
23.599 M
|
0.6%
|
77.7%
|
-41.3
|
229.8%
|
